We are live on ! Find out more
ROIV icon

Roivant Sciences

293 hedge funds and large institutions have $6.57B invested in Roivant Sciences in 2024 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 124 increasing their positions, 68 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 68

14% more capital invested

Capital invested by funds: $5.77B → $6.57B (+$800M)

3.09% more ownership

Funds ownership: 73.88%76.97% (+3.1%)

2% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 52

0% more funds holding

Funds holding: 293293 (0)

11% less funds holding in top 10

Funds holding in top 10: 1917 (-2)

47% less call options, than puts

Call options by funds: $17.6M | Put options by funds: $33.3M

Holders
293
Holders Change
Holders Change %
0%
% of All Funds
4.21%
Holding in Top 10
17
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-10.53%
% of All Funds
0.24%
New
53
Increased
124
Reduced
68
Closed
52
Calls
$17.6M
Puts
$33.3M
Net Calls
-$15.7M
Net Calls Change
-$13.7M
Name Holding Trade Value Shares
Change
Change in
Stake
SIAU
1
SB Investment Advisers (UK)
United Kingdom
$761M -$61.8M -5,427,314 -8%
QF
2
QVT Financial
New York
$759M -$10.5M -926,000 -1%
Viking Global Investors
3
Viking Global Investors
Connecticut
$624M -$171M -15,056,780 -22%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$567M +$29.5M +2,593,910 +6%
BlackRock
5
BlackRock
New York
$484M +$75M +6,591,789 +19%
Vanguard Group
6
Vanguard Group
Pennsylvania
$481M +$381M +33,491,231 +409%
Morgan Stanley
7
Morgan Stanley
New York
$342M +$3.91M +343,865 +1%
RCMNY
8
Rubric Capital Management (New York)
New York
$258M -$6.83M -600,000 -3%
State Street
9
State Street
Massachusetts
$226M +$12.7M +1,118,561 +6%
PSC
10
Patient Square Capital
California
$141M
TSC
11
Two Seas Capital
New York
$112M -$6.76M -593,871 -6%
WP
12
Woodline Partners
California
$100M +$7.8M +685,537 +9%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$89.4M +$16.6M +1,460,205 +23%
Invesco
14
Invesco
Georgia
$73.3M +$5.09M +447,390 +8%
Citadel Advisors
15
Citadel Advisors
Florida
$68.4M +$45.6M +4,004,146 +208%
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$66.4M +$20.7M +1,819,983 +46%
Goldman Sachs
17
Goldman Sachs
New York
$62.2M +$13.6M +1,191,040 +28%
DCM
18
DME Capital Management
New York
$61.3M +$5.66M +497,080 +10%
ACG
19
Anchorage Capital Group
New York
$55.8M
Norges Bank
20
Norges Bank
Norway
$50.6M +$1.65M +145,163 +3%
PC
21
PointState Capital
New York
$47.4M -$4.29M -376,846 -8%
TCIM
22
TOMS Capital Investment Management
New York
$46.3M +$45.7M +4,015,000 New
BCP
23
BlackBarn Capital Partners
New York
$46.2M +$10.2M +900,000 +29%
Loomis, Sayles & Company
24
Loomis, Sayles & Company
Massachusetts
$45.1M +$5.22M +458,601 +13%
PCH
25
Polar Capital Holdings
United Kingdom
$40.4M +$22.8M +2,000,000 +133%

ROIV Hedge Fund Activity: Q3 2024 in Review

293 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q3 2024, worth a combined $6.57B — up 14% from $5.77B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new ROIV positions and 52 closed out — a net gain of 1 holder — while 124 added to existing stakes and 68 trimmed.

The largest buyer was Vanguard Group, adding an estimated $381M. The largest seller was Viking Global Investors, cutting an estimated $171M.

  • 293 institutional investors held Roivant Sciences (ROIV) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $6.57B of Roivant Sciences stock for Q3 2024, up 14% quarter-over-quarter.
  • 53 funds opened new Roivant Sciences positions in Q3 2024 and 52 closed out, a net change of +1 holder.
  • The largest Roivant Sciences buyer in Q3 2024 was Vanguard Group, an estimated $381M added.
  • The largest Roivant Sciences seller in Q3 2024 was Viking Global Investors, an estimated $171M sold.

Based on aggregated 13F filings for Q3 2024.